Cabaletta Bio

Steven Nichtberger, M.D., President and CEO

April 12 | 12:15pm | BioCentriq Ballroom 

Philadelphia, PA

(NASDAQ: CABA)

Cabaletta Bio is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies that have the potential to provide a deep and durable, perhaps curative, treatment for patients with autoimmune diseases. The CABA™ platform – encompassing chimeric antigen receptor T cells for autoimmunity (CARTA: CABA-201, a 4-1BB-containing CD19-CAR T) and Cabaletta Bio’s proprietary chimeric autoantibody receptor T cells (CAART: multiple candidates including DSG3-CAART for mucosal pemphigus vulgaris, MuSK-CAART for MuSK myasthenia gravis) – provides multiple opportunities to treat a broad range of autoimmune diseases.

www.cabalettabio.com



By using this website you agree to accept our Privacy Policy and Terms & Conditions